Small Pharma Archives

Psychedelics News

Small Pharma

Industry

18 Jan 2023

Microdosing DMT to Treat Strokes: Not as Trippy as it Sounds

On January 17th, the company Algernon Pharmaceuticals announced that they had dosed the first patient in their Phase 1 safety trial of the psychedelic drug DMT to treat stroke patients....

By James Hallifax

Industry

28 Dec 2022

2022 Review: 3 Trials Pushing Boundaries of Psychedelic Medicine

James Hallifax takes a look at 3 psychedelic Clinical Trials Pushing Boundaries of Psychedelic Medicine in 2022...

By James Hallifax

Industry

27 Dec 2022

2022 End of Year Review: Small Pharma

Continuing our end-of-year review, we’ll take a moment to update DMT company Small Pharma’s last 12 months....

By Microdose NewsDesk

Industry

22 Dec 2022

Small Pharma Completes Phase IIa Trial and Secures New IP

DMT-development firm Small Pharma has moved its lead candidate drug further through the clinical trial process with the completion of its Phase 2a trial....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

19 Oct 2022

Small Pharma Expands IP With Another US Patent

This is the second United States Patent granted for Small Pharma’s psychedelics portfolio...

By Microdose NewsDesk

Don’t Miss

26 Sep 2022

News You Might Have Missed: Sep 26th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

19 Sep 2022

Small Pharma Completes Enrollment in Phase IIa DMT Trial

Small Pharma has started the week with some positive news....

By Microdose NewsDesk

Finance

27 Jul 2022

Roth Capital Doubles Down on Small Pharma

Roth analyst Elemer Piros has doubled down on Small Pharma, citing the IP value of this new patent....

By Jason Najum

Industry

26 Jul 2022

Small Pharma Granted U.S. Patent for Injectable DMT

Key U....

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result